Table 2.
Baseline sample characteristics across ferritin categories
| Characteristics | Ferritin (ng/ml) | All | |||
|---|---|---|---|---|---|
| <50 | 50–99 | 100–299 | ≥300 | ||
| N patients (row %) | 777 (15) | 1201 (23) | 2236 (43) | 931 (18) | 5145 |
| Age, yr | 69±14 | 69±13 | 70±13 | 69±13 | 69±13 |
| % male | 49 | 56 | 63 | 64 | 59 |
| % Black | 4 | 5 | 5 | 8 | 5 |
| Body mass index, kg/m2 | 29±6 | 29±6 | 29±6 | 29±6 | 29±6 |
| Comorbidities, % | |||||
| Diabetes | 51 | 47 | 45 | 41 | 45 |
| Hypertension | 86 | 88 | 89 | 89 | 88 |
| Coronary artery disease | 31 | 30 | 27 | 27 | 28 |
| HF | 15 | 15 | 14 | 15 | 15 |
| Cerebrovascular disease | 12 | 12 | 11 | 10 | 11 |
| Peripheral vascular disease | 18 | 21 | 19 | 20 | 20 |
| Other cardiovascular disease | 26 | 25 | 24 | 24 | 25 |
| GI bleeding in past year | 2 | 1 | 1 | 1 | 1 |
| Lung disease | 10 | 10 | 9 | 10 | 10 |
| Cancer | 17 | 18 | 18 | 18 | 18 |
| Ulcers/gangrene of extremity | 2 | 2 | 2 | 2 | 2 |
| Neurologic disease | 2 | 3 | 3 | 4 | 3 |
| Psychiatric disorder | 8 | 9 | 8 | 8 | 8 |
| Prescriptions (%) | |||||
| ESA | 9 | 10 | 12 | 25 | 13 |
| Iron, IV or oral | 21 | 18 | 19 | 26 | 21 |
| Labs | |||||
| TSAT, % | 18±9 | 22±9 | 25±9 | 28±12 | 24±10 |
| Ferritin, ng/ml | 31±11 | 74±15 | 177±55 | 537±295 | 196±214 |
| Hgb, g/dl | 12.2±1.8 | 12.4±1.8 | 12.4±1.8 | 11.8±1.9 | 12.3±1.8 |
| eGFR, ml/min per 1.73m2 | 30±11 | 29±11 | 28±11 | 27±11 | 28±11 |
| Albuminuria, % | |||||
| A1 (normal) | 31 | 28 | 28 | 27 | 28 |
| A2 (high) | 35 | 32 | 33 | 32 | 33 |
| A3 (very high) | 26 | 31 | 29 | 30 | 29 |
| A3 (nephrotic) | 9 | 10 | 10 | 11 | 10 |
| Serum albumin, g/dl | 4.0±0.5 | 4.0±0.5 | 4.0±0.5 | 4.0±0.5 | 4.0±0.5 |
| White blood cells, 109/L | 7.3±2.1 | 7.2±2.1 | 7.2±2.0 | 7.2±2.2 | 7.2±2.1 |
Results reported as % or mean±SD. Albuminuria categories: A1: <30 mg/g creatinine, A2: 30–300 mg/g creatinine, A3 (very high): >300–2000 mg/g creatinine, and A3 (nephrotic): >2000 mg/g creatinine.